The total value of sales is less than 0.01% of market cap, indicating routine portfolio management rather than a signal of distress. Monitor next earnings report for any changes in fundamentals, but no immediate concern is warranted.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 17 $588.38entry
- T+1 · 7mo ago −2.54%α −2.34% · $573.44
- T+5 · 7mo ago −3.61%α −4.14% · $567.16
- T+20 · 6mo ago −3.37%α −7.45% · $568.58
- T+60 · 4mo ago −9.62%α −15.91% · $531.79
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Four insiders at United Therapeutics, including CEO Martine Rothblatt and CFO James Edgemon, conducted open-market share sales totaling $1.13 million over a 7-day period, following derivative exercises. The net direction is selling, with the largest sale by director Christopher Patusky.
Key Financial Metrics
Key Facts
- CEO Martine Rothblatt sold $143K, CFO James Edgemon sold $298K, EVP Paul Mahon sold $115K, and Director Christopher Patusky sold $579K in open-market transactions.
- All insiders also exercised stock options or derivatives, including non-cash transactions at $0 strike price, which are routine and non-material.
- Total open-market sales: $1.13M, representing approximately 0.004% of the company's $25.8B market cap, well below the 0.1% threshold for materiality.
- Sales occurred at prices between $573.91 and $578.88 per share, consistent with recent trading levels.
Financial Impact
$1.13 million in open-market share sales
Risk Factors
- Perception risk if media highlights CEO/CFO sales without context
- Potential for short-term sentiment pressure if interpreted as lack of confidence
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1776717516029 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers